Clinical Trials Browser

Phase EARLY_PHASE1 × Multiple Sclerosis × 90 days × Clear all

NCT07337785 2026-05-12

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Multiple Sclerosis, Myasthenia Gravis, Recurrence, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating